Differences

This shows you the differences between two versions of the page.

--- coleman_rotstein [2022/04/19 07:29]
liam [Affiliations]
+++ coleman_rotstein [2022/04/19 19:21] (current)
liam [Affiliations]
@@ Line 13: / Line 13: @@
 Rotstein served as a member of the [[National Advisory Committee on Immunization]] (NACI), and participated in the initial authorization of [[COVID-19 vaccines]] in Canada.((//National Advisory Committee on Immunization (NACI): Membership and representation.// (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html))
-He is the former Director of the Division of Infectious Diseases at [[McMaster University]], past Chair and Secretary of the Infectious Diseases Section of the [[Ontario Medical Association]], former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the [[Association of Medical Microbiology and Infectious Disease Canada]], former President of the [[Canadian Infectious Disease Society]], and former Chair of the Clinical Trials Committee of the [[Canadian Infectious Disease Society]]. In addition, he has been elected a fellow of the [[American College of Physicians]] and the [[Infectious Diseases Society of America]]. He is a reviewer for several international journals and was formerly Associate Editor, Review Section, for the [[Canadian Journal of Infectious Diseases and Medical Microbiology]].
+He is the former Director of the Division of Infectious Diseases at [[McMaster University]], past Chair and Secretary of the Infectious Diseases Section of the [[Ontario Medical Association]], former Co-chair of the Emerging Infectious Diseases Network, former Past-President of the [[Association of Medical Microbiology and Infectious Disease Canada]], former President of the [[Canadian Infectious Disease Society]], and former Chair of the Clinical Trials Committee of the [[Canadian Infectious Disease Society]]. In addition, he has been elected a fellow of the [[American College of Physicians]] and the [[Infectious Diseases Society of America]]. He is a reviewer for several international journals and was formerly Associate Editor, Review Section, for the [[Canadian Journal of Infectious Diseases and Medical Microbiology]], and for [[Biomed Central Infectious Diseases]].
-He is a Professor of Medicine in the Division of Infectious Diseases at the [[University of Toronto]], and an Attending Physician and Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the [[University Health Network]].((//Princess Margaret Cancer Centre Multiple Myeloma Day.// University of Toronto. Retrieved April 18, 2022, from https://archive.ph/HoQqU))
+He is a Professor of Medicine in the Division of Infectious Diseases at the [[University of Toronto]], and an Attending Physician and Director of Oncologic Infectious Diseases of the Immunocompromised Host Infectious Diseases Service at the [[University Health Network]].((//Princess Margaret Cancer Centre Multiple Myeloma Day.// University of Toronto. Retrieved April 18, 2022, from https://archive.ph/HoQqU)) ((//Transplant Research Team.// University Health Network. Retrieved April 19, 2022, from https://archive.ph/4Jvnh)) UHN receives funding from a range of [[pharmaceutical companies]] including [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Apotex]], [[pharmaceutical_companies:Astellas]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Bayer]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Celgene]], [[pharmaceutical_companies:Eisai]], [[pharmaceutical_companies:Eli Lilly]], [[pharmaceutical_companies:EMD Serono]], [[pharmaceutical_companies:Epizyme]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Immunex]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Onyx]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Sanofi]], and [[pharmaceutical_companies:Teva]].((//2021 Annual Report.// The Princess Margaret Cancer Foundation. Retrieved April 19, 2022, from https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf))
+He is a faculty member for [[Mentoring in IBD]], an annual education program for Canadian gastroenterologists.((//Rotstein, Coleman.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/IaYBF)) It is currently funded by [[pharmaceutical_companies:AbbVie]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Organon]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sandoz]], and [[pharmaceutical_companies:Takeda]].((//Sponsors.// Mentoring in IBD. Retrieved April 19, 2022, from https://archive.ph/MMPwq))
+===== Research =====
+Rotstein has published over 160 peer-reviewed papers. His research interests have focused mainly on infections in cancer patients and other immunocompromised hosts as well as fungal infections caused by Candida organisms. He maintains active research interests in clinical trials involving antifungal agents in immunocompromised hosts.
+==== Funding ====
+Rotstein has received grants from [[pharmaceutical_companies:Astellas]], [[pharmaceutical_companies:Chimerix]], [[pharmaceutical_companies:Cidara Therapeutics]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], and other funding (including personal, consulting and speaking fees) from [[pharmaceutical_companies:Avir Pharma]], Merck, [[pharmaceutical_companies:Pendopharm]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Sunovion]], and [[pharmaceutical_companies:Teva]].((Marinelli, T., & Rotstein, C. (2020). //Invasive fungal infections (IFIs) in lung transplant recipients.// Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa603)) ((Pérez-Cortés Villalobos, A., & Rotstein, C. (2021). //Mycobacterium mucogenicum and Mycobacterium neoaurum bacteremia in immunocompromised hosts.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 6(1), 55–62. https://doi.org/10.3138/jammi-2020-0025))
+===== Media =====
+==== Presentations ====
+Rotstein was a speaker at the 2021 Winter Hematology Update hosted by the [[CARE Faculty]], where he presented on the topic of [[COVID-19 vaccines]] in [[oncology]] patients.((Rotstein, C. (2021). //COVID-19 Vaccines in Oncology Patients.// CARE Education. https://web.archive.org/web/20220419144942/https://careeducation.ca/wp-content/uploads/2021/02/Dr.-Rotstein-WHU-Final-Presentation-.pdf)) ((CARE Education. (2021, February 25). //COVID-19 Vaccines in Oncology Patients - Dr. Coleman Rotstein (University Health Network).// YouTube. https://www.youtube.com/watch?v=TCHWvKhxQ5o)) The event was sponsored by [[pharmaceutical_companies:AbbVie]], [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Beigene]], [[pharmaceutical_companies:Bristol-Myers Squibb]], [[pharmaceutical_companies:Janssen]], and [[pharmaceutical_companies:Kite Pharma]] (a [[pharmaceutical_companies:Gilead Sciences]] company).((//Dr. Coleman Rotstein - COVID-19 Vaccines in Oncology Patients.// CARE Education. Retrieved April 19, 2022, from https://archive.ph/cYqF9))